Guangzhou Wondfo Biotech Co Ltd
Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rhe… Read more
Guangzhou Wondfo Biotech Co Ltd (300482) - Net Assets
Latest net assets as of September 2025: CN¥5.56 Billion CNY
Based on the latest financial reports, Guangzhou Wondfo Biotech Co Ltd (300482) has net assets worth CN¥5.56 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.65 Billion) and total liabilities (CN¥1.09 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.56 Billion |
| % of Total Assets | 83.58% |
| Annual Growth Rate | 32.57% |
| 5-Year Change | 88.74% |
| 10-Year Change | 706.44% |
| Growth Volatility | 30.95 |
Guangzhou Wondfo Biotech Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Guangzhou Wondfo Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Guangzhou Wondfo Biotech Co Ltd (2011–2024)
The table below shows the annual net assets of Guangzhou Wondfo Biotech Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.65 Billion | +22.44% |
| 2023-12-31 | CN¥4.61 Billion | +1.70% |
| 2022-12-31 | CN¥4.54 Billion | +29.49% |
| 2021-12-31 | CN¥3.50 Billion | +17.05% |
| 2020-12-31 | CN¥2.99 Billion | +21.66% |
| 2019-12-31 | CN¥2.46 Billion | +14.37% |
| 2018-12-31 | CN¥2.15 Billion | +80.80% |
| 2017-12-31 | CN¥1.19 Billion | +39.22% |
| 2016-12-31 | CN¥854.75 Million | +22.00% |
| 2015-12-31 | CN¥700.64 Million | +123.54% |
| 2014-12-31 | CN¥313.43 Million | +29.80% |
| 2013-12-31 | CN¥241.47 Million | +32.32% |
| 2012-12-31 | CN¥182.48 Million | +26.19% |
| 2011-12-31 | CN¥144.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Guangzhou Wondfo Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4195.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.55 Billion | 63.84% |
| Common Stock | CN¥481.42 Million | 8.67% |
| Other Comprehensive Income | CN¥-21.29 Million | -0.38% |
| Other Components | CN¥1.55 Billion | 27.88% |
| Total Equity | CN¥5.55 Billion | 100.00% |
Guangzhou Wondfo Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Guangzhou Wondfo Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Investors Real Estate Trust
F:WXC1
|
$667.49 Million |
|
Youcare Pharmaceutical Group Co. Ltd. A
SHG:688658
|
$667.79 Million |
|
NB Bancorp, Inc. Common Stock
NASDAQ:NBBK
|
$667.93 Million |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
$667.97 Million |
|
DINE S.A.B. de C.V
MX:DINEB
|
$667.42 Million |
|
Transcat Inc
NASDAQ:TRNS
|
$667.36 Million |
|
Guangxi Liuzhou Pharm Co Ltd
SHG:603368
|
$667.23 Million |
|
VALNEVA SE SP.ADS/2
F:AYJ0
|
$667.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangzhou Wondfo Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,515,967,763 to 5,554,388,042, a change of 1,038,420,279 (23.0%).
- Net income of 561,628,536 contributed positively to equity growth.
- Dividend payments of 196,162,348 reduced retained earnings.
- Share repurchases of 11,059,620 reduced equity.
- Other comprehensive income decreased equity by 27,189,505.
- Other factors increased equity by 711,203,216.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥561.63 Million | +10.11% |
| Dividends Paid | CN¥196.16 Million | -3.53% |
| Share Repurchases | CN¥11.06 Million | -0.2% |
| Other Comprehensive Income | CN¥-27.19 Million | -0.49% |
| Other Changes | CN¥711.20 Million | +12.8% |
| Total Change | CN¥- | 22.99% |
Book Value vs Market Value Analysis
This analysis compares Guangzhou Wondfo Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.63x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 42.04x to 1.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.46 | CN¥19.53 | x |
| 2012-12-31 | CN¥0.59 | CN¥19.53 | x |
| 2013-12-31 | CN¥0.78 | CN¥19.53 | x |
| 2014-12-31 | CN¥1.01 | CN¥19.53 | x |
| 2015-12-31 | CN¥1.93 | CN¥19.53 | x |
| 2016-12-31 | CN¥2.04 | CN¥19.53 | x |
| 2017-12-31 | CN¥2.48 | CN¥19.53 | x |
| 2018-12-31 | CN¥4.45 | CN¥19.53 | x |
| 2019-12-31 | CN¥5.04 | CN¥19.53 | x |
| 2020-12-31 | CN¥6.44 | CN¥19.53 | x |
| 2021-12-31 | CN¥7.56 | CN¥19.53 | x |
| 2022-12-31 | CN¥9.83 | CN¥19.53 | x |
| 2023-12-31 | CN¥10.19 | CN¥19.53 | x |
| 2024-12-31 | CN¥11.97 | CN¥19.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangzhou Wondfo Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.11%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.33%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.29x
- Recent ROE (10.11%) is below the historical average (19.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 21.91% | 17.27% | 0.70x | 1.81x | CN¥17.21 Million |
| 2012 | 20.77% | 16.67% | 0.75x | 1.66x | CN¥19.66 Million |
| 2013 | 24.43% | 23.83% | 0.74x | 1.39x | CN¥34.86 Million |
| 2014 | 31.38% | 26.92% | 0.89x | 1.31x | CN¥67.02 Million |
| 2015 | 17.89% | 29.23% | 0.54x | 1.14x | CN¥55.29 Million |
| 2016 | 17.21% | 26.49% | 0.54x | 1.19x | CN¥60.72 Million |
| 2017 | 20.48% | 18.39% | 0.68x | 1.65x | CN¥107.80 Million |
| 2018 | 15.91% | 18.65% | 0.61x | 1.39x | CN¥114.30 Million |
| 2019 | 17.43% | 18.70% | 0.70x | 1.32x | CN¥165.13 Million |
| 2020 | 22.31% | 22.56% | 0.65x | 1.52x | CN¥349.94 Million |
| 2021 | 18.92% | 18.88% | 0.69x | 1.45x | CN¥299.12 Million |
| 2022 | 27.56% | 21.07% | 0.90x | 1.45x | CN¥762.69 Million |
| 2023 | 10.80% | 17.64% | 0.48x | 1.28x | CN¥36.03 Million |
| 2024 | 10.11% | 18.33% | 0.43x | 1.29x | CN¥6.19 Million |
Industry Comparison
This section compares Guangzhou Wondfo Biotech Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,879,733,462
- Average return on equity (ROE) among peers: 24.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangzhou Wondfo Biotech Co Ltd (300482) | CN¥5.56 Billion | 21.91% | 0.20x | $667.47 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |